Opendata, web and dolomites

MEL-PLEX SIGNED

Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MEL-PLEX" data sheet

The following table provides information about the project.

Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND 

Organization address
address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2
website: www.rcsi.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.melplex.eu
 Total cost 3˙583˙870 €
 EC max contribution 3˙583˙870 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-ETN
 Starting year 2014
 Duration (year-month-day) from 2014-12-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) coordinator 184˙496.00
2    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 501˙120.00
3    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) participant 501˙120.00
4    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 498˙432.00
5    UNIVERSITAET STUTTGART DE (STUTTGART) participant 477˙664.00
6    KRAEFTENS BEKAEMPELSE DK (KOEBENHAVN) participant 290˙081.00
7    ONCOMARK LIMITED IE (DUBLIN) participant 265˙674.00
8    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 265˙674.00
9    OPTIMATA LTD IL (TEL AVIV) participant 260˙300.00
10    PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS EL (GLYFADA) participant 242˙386.00
11    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 55˙381.00
12    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 41˙536.00
13    A. Plaisant Srl. IT (Roma) partner 0.00
14    Apogenix DE (HEIDELBERG) partner 0.00
15    Galderma FR (Chede) partner 0.00
16    Mass. General Hospital US (Boston) partner 0.00
17    Merrimack US (North Andover) partner 0.00
18    Novartis DE (NURNBERG) partner 0.00
19    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) partner 0.00
20    University Berne CH (Berne) partner 0.00

Map

 Project objective

Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines and the associated European training needs provide the foundation for the MEL-PLEX ETN. MEL-PLEX aims to understand the network-level and multi-scale regulation of disease-relevant signalling in melanoma through a combination of quantitative biomedical and computational research approaches that go significantly beyond the current state-of-the-art. Coordinated by the RCSI Centre for Systems Medicine, MEL-PLEX will train 15 early stage researchers through a highly interdisciplinary and intersectoral research training programme. MEL-PLEX comprises 11 beneficiaries and 7 partner organisations from 11 countries, including European and international leaders in personalised melanoma therapy, melanoma systems biology and cancer systems medicine. MEL-PLEX aims to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) will exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) will provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma treatment. The MEL-PLEX ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans across biology, medicine and mathematics, that can navigate confidently between clinical, academic and private sector research environments, and that have developed an innovative and creative mindset to progress research findings towards applications.

 Deliverables

List of deliverables.
Dissemination report 3 Documents, reports 2019-10-08 17:03:05
MEL-PLEX conference Other 2019-10-08 17:03:06
Final dissemination report Documents, reports 2019-10-08 17:03:07
Website Websites, patent fillings, videos etc. 2019-10-08 16:55:03
Dissemination report 2 Documents, reports 2019-10-08 16:55:02
Dissemination report 1 Documents, reports 2019-10-08 16:54:55

Take a look to the deliverables list in detail:  detailed list of MEL-PLEX deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Bruce Moran, Romina Silva, Antoinette S. Perry, William M. Gallagher
Epigenetics of malignant melanoma
published pages: 80-88, ISSN: 1044-579X, DOI: 10.1016/j.semcancer.2017.10.006
Seminars in Cancer Biology 51 2019-10-08
2018 Sébastien De Landtsheer, Philippe Lucarelli, Thomas Sauter
Using Regularization to Infer Cell Line Specificity in Logical Network Models of Signaling Pathways
published pages: , ISSN: 1664-042X, DOI: 10.3389/fphys.2018.00550
Frontiers in Physiology 9 2019-10-08
2018 Erminia Romano, Nicole Rufo, Hannelie Korf, Chantal Mathieu, Abhishek D. Garg, Patrizia Agostinis
BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.24815
Oncotarget 9/25 2019-10-08
2018 Jan Rožanc, Theodore Sakellaropoulos, Asier Antoranz, Cristiano Guttà, Biswajit Podder, Vesna Vetma, Nicole Rufo, Patrizia Agostinis, Vaia Pliaka, Thomas Sauter, Dagmar Kulms, Markus Rehm, Leonidas G. Alexopoulos
Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma
published pages: , ISSN: 1350-9047, DOI: 10.1038/s41418-018-0210-8
Cell Death & Differentiation 2019-10-08
2018 Kotryna Seip, Kjetil Jørgensen, Marco Vincent Haselager, Marco Albrecht, Mads Haugland Haugen, Eivind Valen Egeland, Philippe Lucarelli, Olav Engebraaten, Thomas Sauter, Gunhild Mari Mælandsmo, Lina Prasmickaite
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
published pages: 1-13, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2018.09.023
Cancer Letters 439 2019-10-08
2017 Maddalena Maria Bolognesi, Marco Manzoni, Carla Rossana Scalia, Stefano Zannella, Francesca Maria Bosisio, Mario Faretta, Giorgio Cattoretti
Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections
published pages: 431-444, ISSN: 0022-1554, DOI: 10.1369/0022155417719419
Journal of Histochemistry & Cytochemistry 65/8 2019-10-08
2018 Oleksii S. Rukhlenko, Fahimeh Khorsand, Aleksandar Krstic, Jan Rozanc, Leonidas G. Alexopoulos, Nora Rauch, Keesha E. Erickson, William S. Hlavacek, Richard G. Posner, Silvia Gómez-Coca, Edina Rosta, Cheree Fitzgibbon, David Matallanas, Jens Rauch, Walter Kolch, Boris N. Kholodenko
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
published pages: 161-179.e14, ISSN: 2405-4712, DOI: 10.1016/j.cels.2018.06.002
Cell Systems 7/2 2019-10-08
2018 Greta Del Mistro, Philippe Lucarelli, Ines Müller, Sébastien De Landtsheer, Anna Zinoveva, Meike Hutt, Martin Siegemund, Roland E. Kontermann, Stefan Beissert, Thomas Sauter, Dagmar Kulms
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
published pages: , ISSN: 2056-7189, DOI: 10.1038/s41540-018-0075-y
npj Systems Biology and Applications 4/1 2019-10-08
2017 Nicole Rufo, Abhishek D. Garg, Patrizia Agostinis
The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
published pages: , ISSN: 2405-8033, DOI: 10.1016/j.trecan.2017.07.002
Trends in Cancer 2019-10-08
2016 Francesca M Bosisio, James S Wilmott, Nathalie Volders, Marjorie Mercier, Jasper Wouters, Marguerite Stas, Willeke AM Blokx, Daniela Massi, John F Thompson, Richard A Scolyer, Nicolas van Baren, Joost J van den Oord
Plasma cells in primary melanoma. Prognostic significance and possible role of IgA
published pages: 347-358, ISSN: 0893-3952, DOI: 10.1038/modpathol.2016.28
Modern Pathology 29/4 2019-10-08
2017 Vesna Vetma, Jan Rožanc, Emilie M Charles, Christian T Hellwig, Leonidas G Alexopoulos, Markus Rehm
Examining the In-Vitro Efficacy of the IAP Antagonist Birinapant as a Single-Agent or in Combination with Dacarbazine to Induce Melanoma Cell Death
published pages: , ISSN: 0965-0407, DOI: 10.3727/096504017X14897145996933
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019-10-08
2016 A D Garg, E Romano, N Rufo, P Agostinis
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
published pages: 938-951, ISSN: 1350-9047, DOI: 10.1038/cdd.2016.5
Cell Death and Differentiation 23/6 2019-10-08
2017 Marco Albrecht, Damian Stichel, Benedikt Müller, Ruth Merkle, Carsten Sticht, Norbert Gretz, Ursula Klingmüller, Kai Breuhahn and Franziska Matthäus
TTCA: an R package for the identification of differentially expressed genes in time course microarray data
published pages: , ISSN: 1471-2105, DOI: 10.1186/s12859-016-1440-8
BMC Bioinformatics 2019-10-08
2016 Joost J van den Oord; Bosisio, Francesca Maria
Immunoplasticity in cutaneous melanoma: beyond pure morphology
published pages: , ISSN: 0945-6317, DOI: 10.1007/s00428-016-2058-y
Virchows Archiv 1 2019-10-08
2017 Bruce Moran, Arman Rahman, Katja Palonen, Fiona T. Lanigan, William M. Gallagher
Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation
published pages: 2186-2190, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-1813
Cancer Research 77/9 2019-10-08
2017 Sébastien De Landtsheer, Panuwat Trairatphisan, Philippe Lucarelli, Thomas Sauter
FALCON: a toolbox for the fast contextualization of logical networks
published pages: , ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btx380
Bioinformatics 2019-10-08
2015 Abhishek D. Garg, Lorenzo Galluzzi, Lionel Apetoh, Thais Baert, Raymond B. Birge, José Manuel Bravo-San Pedro, Karine Breckpot, David Brough, Ricardo Chaurio, Mara Cirone, An Coosemans, Pierre G. Coulie, Dirk De Ruysscher, Luciana Dini, Peter de Witte, Aleksandra M. Dudek-Peric, Alberto Faggioni, Jitka Fucikova, Udo S. Gaipl, Jakub Golab, Marie-Lise Gougeon, Michael R. Hamblin, Akseli Hemminki, M
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2015.00588
Frontiers in Immunology 6 2019-10-08
2016 Marco Albrecht, Giuseppe Sciume, Philippe Lucarelli, Thomas Sauter
Thermodynamically constrained averaging theory for cancer growth modelling
published pages: , ISSN: , DOI: 10.1016/j.ifacol.2016.12.141
IFAC Papers Online 49/26 2019-10-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEL-PLEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEL-PLEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More  

POLISS (2019)

Policies for Smart Specialisation

Read More